Page results
-
An evaluation of temporary changes to children and young people’s services in North Central London (NCL) in the autumn and winter of 2020/21 has been published.
-
A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.
-
In May 2020, UCLH invited acclaimed photographer Tom Pilston to take portraits of staff at the height of the Covid-19 pandemic.
-
Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.
-
Researchers at the NIHR UCLH Clinical Research Facility are the first in the world to start a new first-in-human trial investigating a novel treatment, called NVG-111, in patients with Non-Hodgkin lymphoma (NHL) subtypes.
-
People infected with coronavirus have a distinct odour that can be detected by trained dogs with a high degree of accuracy, according to new research involving UCLH.
-
UCLH Director of Research Professor Bryan Williams and Consultant Neuropsychologist at UCLH Professor Lisa Cipolotti have been elected Fellows of the Academy of Medical Sciences in recognition of their exceptional contributions to biomedical and health science.
-
Mild Covid-19 infection is very unlikely to cause lasting damage to the structure or function of the heart, according to a study supported by the NIHR UCLH Biomedical Research Centre and UCLH Charity.
-
UCLH is to lead an initiative to improve care for myeloma patients alongside Oxford University Hospitals NHS Foundation Trust (OUH) and University Hospital Southampton NHS Foundation Trust (UHS).
-
The Com-Cov trial in which UCLH is a site looking at alternating vaccines has been expanded to include the Moderna and Novavax vaccines.
File results
-
FOI/2022/0405 - Treatments C1-esterase inhibitor & immunoglobulin treatments
-
FOI/2022/0407 - Rooftop and greenfield mobile mast site agreements
-
FOI/2022/0411 - Resident Medical Officers/ Resident Doctors/ Senior House Officers supplied by agencies
-
FOI/2022/0421 - Paediatric autoimmune neuropsychiatric disorders
-
FOI/2022/0422 - Annual salary directors
-
FOI/2022/0443 - Trust spend on lost, stolen or damaged patient property
-
FOI/2022/0465 - Treatment of dermatological conditions
-
FOI/2022/0470 - Total spend on agency staff
-
FOI/2022/0485 - ACR laboratory device
-
FOI/2022/0486 - Dermatology dept staff details